Integrum AB Series B (INTEG-B) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.018x

Based on the latest financial reports, Integrum AB Series B (INTEG-B) has a cash flow conversion efficiency ratio of -0.018x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.10 Million ≈ $-333.07K USD) by net assets (Skr172.01 Million ≈ $18.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Integrum AB Series B defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Integrum AB Series B - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Integrum AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Integrum AB Series B Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Integrum AB Series B ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Pulsenmore Ltd
TA:PULS
-0.196x
Fiplasto SA
BA:FIPL
-0.097x
GWR Group Ltd
AU:GWR
0.020x
Andromeda Metals Ltd
AU:ADN
-0.013x
Indofarma Tbk
JK:INAF
0.021x
Mistral Iberia Real Estate SOCIMI S.A.
MC:YMIB
-0.026x
Kintech Electronics Co Ltd
TWO:6210
-0.107x
Puloon Technology Inc
KQ:094940
-0.019x

Annual Cash Flow Conversion Efficiency for Integrum AB Series B (2014–2025)

The table below shows the annual cash flow conversion efficiency of Integrum AB Series B from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Integrum AB Series B worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr172.01 Million
≈ $18.51 Million
Skr-41.02 Million
≈ $-4.41 Million
-0.239x -12.53%
2024-12-31 Skr177.88 Million
≈ $19.14 Million
Skr-37.70 Million
≈ $-4.06 Million
-0.212x -137.47%
2023-12-31 Skr142.79 Million
≈ $15.37 Million
Skr-12.74 Million
≈ $-1.37 Million
-0.089x +48.96%
2022-12-31 Skr143.53 Million
≈ $15.45 Million
Skr-25.10 Million
≈ $-2.70 Million
-0.175x -37.73%
2021-12-31 Skr159.74 Million
≈ $17.19 Million
Skr-20.28 Million
≈ $-2.18 Million
-0.127x +46.48%
2020-12-31 Skr24.29 Million
≈ $2.61 Million
Skr-5.76 Million
≈ $-620.14K
-0.237x +69.94%
2019-12-31 Skr23.73 Million
≈ $2.55 Million
Skr-18.72 Million
≈ $-2.01 Million
-0.789x +49.90%
2018-12-31 Skr16.05 Million
≈ $1.73 Million
Skr-25.28 Million
≈ $-2.72 Million
-1.575x -62.44%
2017-12-31 Skr18.00 Million
≈ $1.94 Million
Skr-17.45 Million
≈ $-1.88 Million
-0.969x -238.90%
2016-12-31 Skr10.53 Million
≈ $1.13 Million
Skr-3.01 Million
≈ $-324.30K
-0.286x +88.15%
2015-12-31 Skr1.14 Million
≈ $122.14K
Skr-2.74 Million
≈ $-294.76K
-2.413x -312.76%
2014-12-31 Skr1.13 Million
≈ $122.04K
Skr-663.00K
≈ $-71.35K
-0.585x --

About Integrum AB Series B

ST:INTEG-B Sweden Medical Devices
Market Cap
$22.88 Million
Skr212.65 Million SEK
Market Cap Rank
#24689 Global
#489 in Sweden
Share Price
Skr8.17
Change (1 day)
-0.24%
52-Week Range
Skr6.96 - Skr43.10
All Time High
Skr102.00
About

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoidi… Read more